Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-Year results from the EFOS study

Journal of Rheumatology

Volumn 39, Issue 3, 2012, Pages 600-609

  Karras, Dimitrios ^a   Stoykov, Ivaylo ^e   Lems, Willem F ^b   Langdahl, Bente L ^c   Ljunggren, Östen ^d   Barrett, Annabel ^e   Walsh, J Bernard ^f   Fahrleitner Pammer, Astrid ^g   Rajzbaum, Gerald ^h   Jakob, Franz ⁱ   Marin, Fernando ^e  

^a Veterans Administration Hospital   (Greece)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

^e ELI LILLY AND COMPANY   (United States)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h SAINT JOSEPH HOSPITAL   (France)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Back pain; Fracture; Glucocorticoids; Osteoporosis; Quality of life; Teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

AGED; ARTICLE; BACKACHE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT DURATION; VISUAL ANALOG SCALE;

AGED; ARTHRITIS, RHEUMATOID; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN MEASUREMENT; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84857816957     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110947     Document Type: Article

References (35)

1. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28. (Pubitemid 47389469)
2. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality [editorial]. Arthritis Rheum 2007;56:3518-22. (Pubitemid 350100684)
3. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-8.
4. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-29. (Pubitemid 37409336)
5. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. (Pubitemid 350106710)
6. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-55.
7. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-20.
8. Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Langdahl BL, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008;24:377-84. (Pubitemid 351294388)
9. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93.
10. Fahrleitner-Pammer A, Langdahl B, Marin F, Jakob F, Karras D, Barrett A, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011;22:2709-19.
11. Forsteo (teriparatide). Summary of product characteristics. London: European Medicines Agency; 2011. [Internet. Accessed November 23, 2011.] Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hu man/medicines/000425/human-med-000798.jsp&murl=menus/med icines/medicines.jsp&jsenabled=true
12. Ross PD. Clinical consequences of vertebral fractures. Am J Med 1997;103:30S-43S. (Pubitemid 27386440)
13. Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001;33:337-43. (Pubitemid 32675374)
14. Szende A, Williams A, editors. Measuring self-reported population health: An international perspective based on EQ-5D. Budapest: SpringMed; 2004.
15. Liang YK, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
16. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
17. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-99. (Pubitemid 41103445)
18. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000. (Pubitemid 30350061)
19. Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2009;7:23-6.
20. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone 2010;46:564-70.
21. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001;16:97-103. (Pubitemid 32046193)
22. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010;47:169-80.
23. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
24. Rizzoli R. How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis? Nat Clin Pract Endocrinol Metab 2008;4:372-3. (Pubitemid 351881857)
25. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 2011;63:325-8.
26. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.
27. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46. (Pubitemid 29534328)
28. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-16.
29. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 2008;473:218-24.
30. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modelling of QCT scans in women with osteoporosis. J Bone Miner Res 2007;22:149-57. (Pubitemid 46032608)
31. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: Results from the EUROFORS study. J Bone Miner Res 2009;24:1672-80.
32. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status. Osteoporos Int 2009;20:2095-104.
33. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26.
34. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. (Pubitemid 32402100)
35. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;2:CD000952.